Is Amgen Stock a Buy?
(NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant and Dow Jones Industrial Average component, pending clinical-trial data from its drug pipeline has added a layer of uncertainty.
On the other hand, the company continues to deliver strong growth with overall positive fundamentals. So is now a good time to pick up some Amgen shares? Here's what you need to know.
Amgen is recognized as a biotech pioneer with a long history of groundbreaking discoveries. From developing Epogen in the 1980s as one of the first recombinant DNA technology-based treatments for anemia to launching the first-of-its-kind monoclonal-antibody therapy against cancer with Neulasta in 2003, that tradition of innovation has continued.
Source Fool.com
Amgen Inc. Stock
The stock is one of the favorites of our community with 41 Buy predictions and 4 Sell predictions.
On the other hand, the target price of 336 € is below the current price of 355.4 € for Amgen Inc., so the potential is actually -5.46%.
